Literature DB >> 17280861

Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A.

Zonggao Shi1, Maria J Henwood, Peter Bannerman, Dalia Batista, Anelia Horvath, Marta Guttenberg, Constantine A Stratakis, Adda Grimberg.   

Abstract

OBJECTIVE: Primary pigmented nodular adrenocortical disease (PPNAD) can occur as an isolated trait or part of Carney complex, a familial lentiginosis-multiple endocrine neoplasia syndrome frequently caused by mutations in PRKAR1A, which encodes the 1alpha regulatory subunit of protein kinase A (PKA). Because alterations in the insulin-like growth factor (IGF) axis, particularly IGF-II and IGF binding protein (IGFBP)-2 overexpression, have been implicated in sporadic adrenocortical tumors, we sought to examine the IGF axis in PPNAD.
DESIGN: RNA samples and paraffin-embedded sections were procured from adrenalectomy specimens of patients with PPNAD. Changes in expression of IGF axis components were evaluated by real-time quantitative RT-PCR and immunohistochemistry. NCI-H295R cells were used to study PKA and IGF axis signaling in adrenocortical cells in vitro.
RESULTS: IGFBP-2 mRNA level distinguished between the two genetic subtypes of this disease; increased IGFBP-2 expression in PRKAR1A mutation-positive PPNAD tissues was also confirmed by immunohistochemistry. Moreover, PKA inhibitors increased IGFBP-2 expression in NCI-H295R adrenocortical cells, and anti-IGFBP-2 antibody reduced their proliferation.
CONCLUSIONS: IGFBP-2 expression is increased in PPNAD caused by PRKAR1A mutations, and in adrenocortical cancer cells. This is the first evidence for PKA-dependent regulation of IGFBP-2 expression in adrenocortical cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280861      PMCID: PMC2577759          DOI: 10.1016/j.ghir.2006.12.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  46 in total

1.  Identification of a promoter element which participates in cAMP-stimulated expression of human insulin-like growth factor-binding protein-1.

Authors:  A Suwanichkul; L A DePaolis; P D Lee; D R Powell
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

2.  Bilateral primary pigmented nodular adrenocortical disease. Rare cause of the Cushing syndrome.

Authors:  B V Shenoy; P C Carpenter; J A Carney
Journal:  Am J Surg Pathol       Date:  1984-05       Impact factor: 6.394

3.  Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity?

Authors:  Daniel F Gunther; Isabelle Bourdeau; Ludmila Matyakhina; David Cassarino; David E Kleiner; Kurt Griffin; Nickolas Courkoutsakis; Mones Abu-Asab; Maria Tsokos; Meg Keil; J Aidan Carney; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

4.  Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo.

Authors:  A Hoeflich; R Reisinger; B S Schuett; M W Elmlinger; V C Russo; G A Vargas; P M Jehle; H Lahm; I Renner-Müller; E Wolf
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

5.  Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2.

Authors:  Shilla Chatterjee; Eun Sung Park; Melvyn S Soloff
Journal:  Int J Urol       Date:  2004-10       Impact factor: 3.369

Review 6.  The NCI-H295 cell line: a pluripotent model for human adrenocortical studies.

Authors:  W E Rainey; I M Bird; J I Mason
Journal:  Mol Cell Endocrinol       Date:  1994-04       Impact factor: 4.102

7.  Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.

Authors:  B S Schütt; M Langkamp; U Rauschnabel; M B Ranke; M W Elmlinger
Journal:  J Mol Endocrinol       Date:  2004-06       Impact factor: 5.098

8.  Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth.

Authors:  Joseph J Pereira; Tim Meyer; Susan E Docherty; Hugh H Reid; John Marshall; Erik W Thompson; Jamie Rossjohn; John T Price
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  Increased activity of catalase in tumor cells overexpressing IGFBP-2.

Authors:  A Hoeflich; O Fettscher; G Preta; H Lahm; H J Kolb; E Wolf; M M Weber
Journal:  Horm Metab Res       Date:  2003 Nov-Dec       Impact factor: 2.936

10.  Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.

Authors:  C A Stratakis; J A Carney; J P Lin; D A Papanicolaou; M Karl; D L Kastner; E Pras; G P Chrousos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more
  3 in total

Review 1.  The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms.

Authors:  Anna Angelousi; Georgios Kyriakopoulos; Narjes Nasiri-Ansari; Margarita Karageorgou; Eva Kassi
Journal:  Ann Transl Med       Date:  2018-06

2.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18

3.  Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors.

Authors:  Kiran S Nadella; Annabel Berthon; Madson Q Almeida; Isaac Levy; Fabio R Faucz; Constantine A Stratakis
Journal:  Endocrine       Date:  2021-01-09       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.